Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for EVRYSDIⓇ (risdiplam) for the treatment of adults and children with spinal muscular atrophy (SMA)

Hoffmann-La Roche Limited (Roche Canada) today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for EVRYSDI® (risdiplam), a pre-mRNA splicing modifier of survival of motor neuron 2 (SMN2) designed to treat SMA, indicated for the treatment of spinal muscular atrophy (SMA) in patients two months of age or older.1

NewsCatherine LamontagneFebruary 21, 2022Roche Canada, pCPA